Fique off-line com o app Player FM !
Podcasts que valem a pena ouvir
PATROCINADO
1 ICE CUBE in the Trap! | 85 South Show Podcast 52:43
Precision Medicine in Oncology: Ep.9 DEBATE - Is PARP inhibitor maintenance therapy in first-line BRCA mutated ovarian cancer a curative-intent strategy?
Manage episode 316945930 series 2812899
Welcome to episode 9 of IMPACT Medicom’s podcast series on Precision Medicine in Oncology, the second episode in a 3-part series on ovarian cancer. This episode, hosted by IMPACT Medicom’s Sarah Doucette, features a debate on whether first-line maintenance therapy with PARP inhibitors can be considered a curative strategy in patients with advanced, BRCA-mutated epithelial ovarian cancer.
Our Guests:
Dr. Taymaa May
Taymaa May is a surgical scientist at the University Health Network and an Associate Professor at the University of Toronto. Dr. May is the surgical oncology lead for Toronto central south, Ontario Health/Cancer Care Ontario and the chair of the Gynecologic Oncology Group of Ontario. She is the director of clinical specialty programs in the department of surgical oncology and a member of the Princess Margaret executive. She is also the current chair of the Gynecologic Oncology of Canada’s (GOC) Annual General Meeting and is a member of GOC’s board of directors. Dr. May’s research focuses on surgical innovation and translational research in ovarian cancer.
Dr. James Bentley
Dr. James Bentley is a Professor and Head of the Department of Obstetrics and Gynaecology at Dalhousie University. He is a Past President of the International Federation of Cervical Pathology and Colposcopy (IFCPC), the Society of Gynaecologic Oncology of Canada (GOC), and the Society of Canadian Colposcopists, and is the past Chair of the Royal College Nucleus Committee for Gynecologic Oncology. He continues to serve on numerous national and provincial committees involved with cervical cancer screening and gynecological cancer. Dr. Bentley's clinical interests lie in the field of cervical cancer prevention, colposcopy, clinical trials including the application of HPV Vaccines and chemotherapy trials.
Links:
SOLO-1 5-year update: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00531-3/fulltext
Correlation between BRCA status and surgical cytoreduction: https://www.gynecologiconcology-online.net/article/S0090-8258(21)00540-0/fulltext
This podcast episode was sponsored by AstraZeneca Canada and Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
68 episódios
Manage episode 316945930 series 2812899
Welcome to episode 9 of IMPACT Medicom’s podcast series on Precision Medicine in Oncology, the second episode in a 3-part series on ovarian cancer. This episode, hosted by IMPACT Medicom’s Sarah Doucette, features a debate on whether first-line maintenance therapy with PARP inhibitors can be considered a curative strategy in patients with advanced, BRCA-mutated epithelial ovarian cancer.
Our Guests:
Dr. Taymaa May
Taymaa May is a surgical scientist at the University Health Network and an Associate Professor at the University of Toronto. Dr. May is the surgical oncology lead for Toronto central south, Ontario Health/Cancer Care Ontario and the chair of the Gynecologic Oncology Group of Ontario. She is the director of clinical specialty programs in the department of surgical oncology and a member of the Princess Margaret executive. She is also the current chair of the Gynecologic Oncology of Canada’s (GOC) Annual General Meeting and is a member of GOC’s board of directors. Dr. May’s research focuses on surgical innovation and translational research in ovarian cancer.
Dr. James Bentley
Dr. James Bentley is a Professor and Head of the Department of Obstetrics and Gynaecology at Dalhousie University. He is a Past President of the International Federation of Cervical Pathology and Colposcopy (IFCPC), the Society of Gynaecologic Oncology of Canada (GOC), and the Society of Canadian Colposcopists, and is the past Chair of the Royal College Nucleus Committee for Gynecologic Oncology. He continues to serve on numerous national and provincial committees involved with cervical cancer screening and gynecological cancer. Dr. Bentley's clinical interests lie in the field of cervical cancer prevention, colposcopy, clinical trials including the application of HPV Vaccines and chemotherapy trials.
Links:
SOLO-1 5-year update: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00531-3/fulltext
Correlation between BRCA status and surgical cytoreduction: https://www.gynecologiconcology-online.net/article/S0090-8258(21)00540-0/fulltext
This podcast episode was sponsored by AstraZeneca Canada and Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
68 episódios
Todos os episódios
×1 Integrating Non-Covalent BTK Inhibitors in CLL: Navigating a Rapidly Evolving Treatment Landscape 17:37
1 Highlights from EHA 2024 - Updates on the Treatment of CLL 42:13
1 LIVE FROM EHA 2024 - Sonrotoclax plus Zanubrutinib in R/R CLL 16:33
1 Cutting Edge Advances in the Treatment of Lung Cancer 15:13
1 Precision Medicine Series: Ep15: Biomarkers in Upper GI Cancers 41:28
1 Immunotherapy for Kidney Transplant Patients with Skin Cancer 21:32
1 Management of Cutaneous Squamous Cell Carcinoma (cSCC): A Surgeon’s Perspective 24:11
1 LIVE FROM ASH 2023: Isa-CYBORD induction chemotherapy in newly diagnosed, transplant eligible MM 16:58
1 Live from ASH 2023: Dr Brown Discusses Updated Results of the ALPINE Trial in CLL 13:48
1 First-line treatment strategies for the management of la/mUC: S2 Ep 5 - ESMO 2023: Discussion on 1L LA/mUC 32:28
1 First Line la/mUC Evolving Treatment Strategies: S2 Ep 4 - Round Table Discussion 26:41
1 First Line la/mUC Evolving Treatment Strategies: S2 Ep 3 - Case Discussion 8:07
1 First Line la/mUC Evolving Treatment Strategies: S2 Ep 2 - First-Line Treatment 14:52
1 First Line la/mUC Evolving Treatment Strategies: S2 Ep 1 - Unmet Needs 10:38
Bem vindo ao Player FM!
O Player FM procura na web por podcasts de alta qualidade para você curtir agora mesmo. É o melhor app de podcast e funciona no Android, iPhone e web. Inscreva-se para sincronizar as assinaturas entre os dispositivos.